Core Viewpoint - Shenwei Pharmaceutical Group has received approval for its self-developed Shengxian Decoction Granules, marking its fourth classic prescription approval and the first of its kind in Hebei Province [1] Group 1: Product Development - Shengxian Decoction Granules are based on a prescription from the Qing Dynasty physician Zhang Xichun, consisting of five medicinal ingredients: Astragalus, Anemarrhena, Bupleurum, Platycodon, and Cimicifuga, aimed at treating symptoms of "Qi deficiency" such as shortness of breath and fatigue [1] - The company has established a comprehensive R&D system since 2017, focusing on classic prescriptions, which includes ancient text research, medicinal material tracing, process innovation, and clinical validation [1] Group 2: Market Position - Shenwei Pharmaceutical Group is one of the earliest companies in China to conduct research on classic prescriptions and holds one of the highest numbers of classic prescription projects [1] - The company has over 100 classic prescriptions and innovative traditional Chinese medicine projects under development, covering various therapeutic areas including respiratory, digestive, and gynecological systems, with several products already in the application stage [1]

Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - The function and indications of Shengxian Decoction Granules include tonifying Qi and lifting the sinking, used for the syndrome of Qi sinking, characterized by symptoms such as shortness of breath, difficulty in breathing, and weak pulse [1]

Group 1 - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - The function and indications of Shengxian Decoction Granules include tonifying Qi and lifting the sinking of Qi, used for symptoms of Qi deficiency with manifestations such as shortness of breath, difficulty in breathing, and weak pulse [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" for "Shengxian Decoction Granules" from the National Medical Products Administration [1] Group 1 - The "Shengxian Decoction Granules" are indicated for the treatment of Qi deficiency syndrome, characterized by symptoms such as shortness of breath, difficulty in breathing, and weak pulse [1] - The product is specifically used for conditions related to "Qi sinking" [1]

Group 1 - The core point of the article is that Jilin Aodong Pharmaceutical Group Co., Ltd. has received a drug registration certificate for "Shengxian Decoction Granules" from the National Medical Products Administration [1] - As of the first half of 2025, the revenue composition of Jilin Aodong is as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - The current market capitalization of Jilin Aodong is 22.5 billion yuan [1]